MedTrace Logo

TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease

NCT03539380 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-09-27

No results posted yet for this study

Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide continued access to TRx0237 to individual patients with early and mild-moderate Alzheimer's disease who do not qualify for participation in an ongoing clinical trial. Eligible participants must have previously completed participation in a clinical trial of TRx0237 conducted by TauRx or have previously taken TRx0237 in a compassionate use program, among other criteria. Patients will be considered where a physician can demonstrate clinical benefit for a patient not meeting these criteria; in these cases, TauRx will consider participation of the patient on a case-by-case basis.

Conditions

  • Alzheimer Disease

Interventions

DRUG

TRx0237

Starting dose of TRx0237 16 mg/day (unless enrolled under earlier version of protocol and are on an established dose), with flexible dosing after 3 months (4-16 mg/day)

Sponsors & Collaborators

  • TauRx Therapeutics Ltd

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03539380 on ClinicalTrials.gov